Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib in adult patients with solid tumors
NCT02122913Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2014
- Primary completion
- Feb 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of larotrectinib in solid tumor, sponsored by Bayer. Primary endpoints: Number of participants with adverse events at 25 months, Severity of adverse events at 25 months and 2 more. Started May 2014; status: completed.
02
Drugs
larotrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02122913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122913.